EspeRare (CH) – Caroline Kant

In collaboration with patients, EspeRare is rescuing and repositioning therapies for rare diseases, accelerating the development of accessible treatments for these patients underserved by the pharmaceutical industry. A treatment currently in phase III testing and expected on the market in 2026 could revolutionize the treatment of genetic diseases by becoming the first to be administered in utero.